Want to see XBIO full AI Analyst Report?
XBIO Stock Chart & Stats
$3.82
-$0.14(-5.30%)
At close: 4:00 PM EDT
$3.82
-$0.14(-5.30%)
Day’s Range― - ―
52-Week Range$1.87 - $13.93
Previous Close$2.64
Volume3.06K
Average Volume (3M)117.89K
Market Cap
$7.01M
Enterprise Value$0.20
Total Cash (Recent Filing)$6.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding2,343,181
10 Day Avg. Volume283,198
30 Day Avg. Volume117,890
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginRevenue growth and an approximately 80% TTM gross margin indicate that reported demand is expanding while the revenue base carries substantial gross profit. If maintained, this combination can provide more resources to support development and improve operating leverage as programs advance.
Debt-free Balance SheetA debt-free balance sheet reduces interest expense, refinancing exposure, and creditor pressure while preserving flexibility for research investment. This conservative leverage profile gives Xenetic more room to manage development uncertainty, although it does not eliminate the need to fund operating losses.
Expanded Clinical PipelineThe proposed acquisition could materially broaden Xenetic's development platform beyond its existing biologics focus, adding multiple NET-targeting programs and clinical milestones. A wider pipeline may diversify scientific risk and create more opportunities for value creation if the transaction and programs progress successfully.
Bears Say
Persistent UnprofitabilityDeeply negative net margin, EBIT, and EBITDA show that current revenue is not yet sufficient to cover operating and development costs. Until the business reaches greater scale or improves expense efficiency, earnings remain exposed to continued losses and the company has limited internally generated funding capacity.
Ongoing Cash BurnNegative operating and free cash flow indicate that Xenetic continues to consume cash in running and developing the business. Even though the burn rate improved from earlier periods, sustained cash deficits can require external financing and may constrain the pace of investment or increase future dilution.
Acquisition Dilution And Execution RiskAn all-stock transaction that gives Santersus investors approximately 85% ownership would substantially dilute existing Xenetic holders and shift control toward the acquired company. The need for shareholder approval, regulatory filings, and closing conditions also creates execution risk before the expanded pipeline can contribute.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.87 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $7.01M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Nov 06, 2026 which is in 44 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Aug 07, 2026. The company reported -$0.41 earnings per share for the quarter.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,343,181 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.41 in its last earnings report. Following the earnings report the stock price went up 11.228%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
4.27% Insiders
0.85% Mutual Funds
0.12% Other Institutional Investors
94.23% Public Companies and
Individual Investors